Methotrexate Biologic Composition Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional combination therapies for inflammatory autoimmune diseases involving methotrexate and biologics are costly, stressful, and prone to reduced clinical efficacy due to physicochemical instability and high dosing requirements, leading to increased side effects and intolerance.
Innovation Solution
A pharmaceutical composition combining methotrexate or its salt/derivative with a pharmaceutically active biopharmaceutical in a solvent, enhancing solubility, thermodynamic stability, and binding affinity, allowing for lower dosing and improved tolerability, and reducing the need for frequent injections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional combination therapies use high doses of biologics and methotrexate, then therapeutic efficacy is maintained, but side effects increase and patient tolerability decreases
Solution Approach 1:
The patent changes the concentration parameters by using lower doses of biologic (0.1-10 mg/ml) and methotrexate (0.01-1 mg/ml) while maintaining therapeutic efficacy through optimized formulation composition including pH adjustment (6.0-8.0), excipients, and stabilizers that enhance drug stability and bioavailability at reduced concentrations
2Ease of operation
If biologics are administered in ready-to-use liquid formulations, then administration convenience is improved, but physicochemical stability decreases leading to loss of biological activity
Solution Approach 1:
The patent applies preliminary stabilization actions by incorporating pH adjusters, excipients, and stabilizers into the liquid formulation before administration, and by optimizing the formulation composition in advance to prevent degradation during storage and administration, thereby maintaining both convenience and stability
Solution Approach 2:
The patent introduces intermediary substances including pH adjusters (buffers), excipients (surfactants, sugars, amino acids), and stabilizers that act as mediators between the biologic and the liquid environment, protecting the biologic from degradation while maintaining solubility and stability in ready-to-use formulations
3Reliability
If combination therapy frequency is increased, then treatment effectiveness is improved, but treatment complexity and cost increase
Solution Approach 1:
The patent merges two separate therapies (biologic and methotrexate) into a single combined liquid formulation that can be administered as one injection, reducing treatment complexity while maintaining the synergistic therapeutic effectiveness of both agents through optimized concentration ratios and formulation compatibility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides improved stability and efficacy of biologics, enabling self-administration, reduced side effects, and lower costs, with enhanced pharmacodynamic effects and increased stability of biologics in the body, leading to better treatment outcomes for inflammatory autoimmune diseases.
Implementation Method 1
enhancing solubility, thermodynamic stability, and binding affinity
Implementation Method 2
enhancing solubility, thermodynamic stability, and binding affinity
Implementation Method 3
enhancing solubility, thermodynamic stability, and binding affinity
Data Source
AI summary
Pharmaceutical compositions containing methotrexate or a pharmaceutically acceptable salt, hydrate, or derivative thereof, and a pharmaceutically active biopharmaceutical in a pharmaceutically acceptable solvent, are provided. Such compositions find medicinal use, inter alia, in the treatment of inflammatory autoimmune diseases such as rheumatoid arthritis.